{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:03:41Z","timestamp":1790089421074,"version":"4.0.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LR16C050001"],"award-info":[{"award-number":["LR16C050001"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32471300"],"award-info":[{"award-number":["32471300"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Differ"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>DEPTOR, a naturally occurring inhibitor of mTOR, plays crucial roles in tumorigenesis and is frequently dysregulated in a variety of human cancers. Interestingly, DEPTOR could act either as a tumor suppressor or as an oncogene in a manner dependent of cellular context or tissue environment. Whether and how DEPTOR regulates lymphomagenesis remains elusive. In this study, we report that in a mouse lymphoma model induced by heterozygous <jats:italic>Pten<\/jats:italic> loss, <jats:italic>Deptor<\/jats:italic> knockout (KO) markedly accelerates lymphomagenesis, whereas degradation-resistant <jats:italic>Deptor<\/jats:italic>\n            <jats:sup>\n              <jats:italic>S275A<\/jats:italic>\n            <\/jats:sup> knock-in (KI) variant significantly inhibits it. Furthermore, <jats:italic>Deptor<\/jats:italic> KO mice spontaneously developed lymphomas in the later stages of their lifespan, and <jats:italic>Deptor<\/jats:italic> KO further shortened overall lifespan in <jats:italic>Pten<\/jats:italic>\n            <jats:sup>\n              <jats:italic>fl\/fl<\/jats:italic>\n            <\/jats:sup>\n            <jats:italic>;MMTV-Cre<\/jats:italic> mice. Consistently, DEPTOR protein levels are significantly lower in human lymphoma tissues, as compared to normal lymph nodes. Mechanistically, DEPTOR, on one hand, enhances the interaction of EGFR to HUWE1 E3 ubiquitin ligase for targeted ubiquitination and proteasomal degradation, and subsequent inactivation of the MAPK signal. On the other hand, DEPTOR inactivates both mTORC1 and mTORC2 signals. Collectively, our study demonstrated that DEPTOR is a tumor suppressor that inhibits lymphomagenesis upon <jats:italic>Pten<\/jats:italic>-loss. The strategy that reactivates DEPTOR could be a promising approach for the treatment of lymphoma.<\/jats:p>","DOI":"10.1038\/s41418-025-01497-5","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:40:10Z","timestamp":1743727210000},"page":"1820-1832","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["DEPTOR suppresses lymphomagenesis by promoting EGFR degradation via HUWE1 E3 ligase"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6842-3673","authenticated-orcid":false,"given":"Xiufang","family":"Xiong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengpeng","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danrui","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruirui","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baohui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5841-4287","authenticated-orcid":false,"given":"Yi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4610-4182","authenticated-orcid":false,"given":"Yongchao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"1497_CR1","first-page":"34","volume":"101","author":"WD Lewis","year":"2020","unstructured":"Lewis WD, Lilly S, Jones KL. Lymphoma: Diagnosis and Treatment. Am Fam Physician. 2020;101:34\u201341.","journal-title":"Am Fam Physician"},{"key":"1497_CR2","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1146\/annurev-pathol-020117-043803","volume":"13","author":"KSJ Elenitoba-Johnson","year":"2018","unstructured":"Elenitoba-Johnson KSJ, Lim MS. New Insights into Lymphoma Pathogenesis. Annu Rev Pathol. 2018;13:193\u2013217.","journal-title":"Annu Rev Pathol"},{"key":"1497_CR3","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1182\/blood-2004-12-4621","volume":"106","author":"A Hachem","year":"2005","unstructured":"Hachem A, Gartenhaus RB. Oncogenes as molecular targets in lymphoma. Blood. 2005;106:1911\u201323.","journal-title":"Blood"},{"key":"1497_CR4","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.2217\/fon.13.113","volume":"9","author":"A Arita","year":"2013","unstructured":"Arita A, McFarland DC, Myklebust JH, Parekh S, Petersen B, Gabrilove J, et al. Signaling pathways in lymphoma: pathogenesis and therapeutic targets. Future Oncol. 2013;9:1549\u201371.","journal-title":"Future Oncol"},{"key":"1497_CR5","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/s41580-019-0199-y","volume":"21","author":"GY Liu","year":"2020","unstructured":"Liu GY, Sabatini DM. mTOR at the nexus of nutrition, growth, ageing and disease. Nat Rev Mol Cell Biol. 2020;21:183\u2013203.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1497_CR6","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.cell.2017.03.035","volume":"169","author":"RA Saxton","year":"2017","unstructured":"Saxton RA, Sabatini DM. mTOR Signaling in Growth, Metabolism, and Disease. Cell. 2017;169:361\u201371.","journal-title":"Cell"},{"key":"1497_CR7","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.clml.2014.01.007","volume":"14","author":"JR Westin","year":"2014","unstructured":"Westin JR. Status of PI3K\/Akt\/mTOR pathway inhibitors in lymphoma. Clin Lymphoma Myeloma Leuk. 2014;14:335\u201342.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1497_CR8","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41375-022-01749-0","volume":"37","author":"W Xu","year":"2023","unstructured":"Xu W, Berning P, Erdmann T, Grau M, Bettazova N, Zapukhlyak M, et al. mTOR inhibition amplifies the anti-lymphoma effect of PI3Kbeta\/delta blockage in diffuse large B-cell lymphoma. Leukemia. 2023;37:178\u201389.","journal-title":"Leukemia"},{"key":"1497_CR9","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.cell.2009.03.046","volume":"137","author":"TR Peterson","year":"2009","unstructured":"Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM, et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell. 2009;137:873\u201386.","journal-title":"Cell"},{"key":"1497_CR10","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1152\/physrev.00064.2017","volume":"98","author":"A Caron","year":"2018","unstructured":"Caron A, Briscoe DM, Richard D, Laplante M. DEPTOR at the Nexus of Cancer, Metabolism, and Immunity. Physiol Rev. 2018;98:1765\u2013803.","journal-title":"Physiol Rev"},{"key":"1497_CR11","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1038\/s41388-019-1085-y","volume":"39","author":"X Chen","year":"2020","unstructured":"Chen X, Xiong X, Cui D, Yang F, Wei D, Li H, et al. DEPTOR is an in vivo tumor suppressor that inhibits prostate tumorigenesis via the inactivation of mTORC1\/2 signals. Oncogene. 2020;39:1557\u201371.","journal-title":"Oncogene"},{"key":"1497_CR12","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.canlet.2021.07.031","volume":"519","author":"L Gong","year":"2021","unstructured":"Gong L, Shu J, Chen X, Pan H, Chen G, Bi Y, et al. DEPTOR inhibits lung tumorigenesis by inactivating the EGFR-mTOR signals. Cancer Lett. 2021;519:263\u201376.","journal-title":"Cancer Lett"},{"key":"1497_CR13","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.molcel.2011.08.029","volume":"44","author":"Y Zhao","year":"2011","unstructured":"Zhao Y, Xiong X, Sun Y. DEPTOR, an mTOR inhibitor, is a physiological substrate of SCF(betaTrCP) E3 ubiquitin ligase and regulates survival and autophagy. Mol Cell. 2011;44:304\u201316.","journal-title":"Mol Cell"},{"key":"1497_CR14","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.molcel.2011.09.005","volume":"44","author":"S Duan","year":"2011","unstructured":"Duan S, Skaar JR, Kuchay S, Toschi A, Kanarek N, Ben-Neriah Y, et al. mTOR generates an auto-amplification loop by triggering the betaTrCP- and CK1alpha-dependent degradation of DEPTOR. Mol Cell. 2011;44:317\u201324.","journal-title":"Mol Cell"},{"key":"1497_CR15","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.molcel.2011.08.030","volume":"44","author":"D Gao","year":"2011","unstructured":"Gao D, Inuzuka H, Tan MK, Fukushima H, Locasale JW, Liu P, et al. mTOR drives its own activation via SCF(betaTrCP)-dependent degradation of the mTOR inhibitor DEPTOR. Mol Cell. 2011;44:290\u2013303.","journal-title":"Mol Cell"},{"key":"1497_CR16","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1593\/neo.12532","volume":"14","author":"Y Zhao","year":"2012","unstructured":"Zhao Y, Sun Y. Targeting the mTOR-DEPTOR pathway by CRL E3 ubiquitin ligases: therapeutic application. Neoplasia. 2012;14:360\u20137.","journal-title":"Neoplasia"},{"key":"1497_CR17","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1073\/pnas.96.4.1563","volume":"96","author":"K Podsypanina","year":"1999","unstructured":"Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM, et al. Mutation of Pten\/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA. 1999;96:1563\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1497_CR18","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/S0960-9822(07)00488-5","volume":"8","author":"A Suzuki","year":"1998","unstructured":"Suzuki A, de la Pompa JL, Stambolic V, Elia AJ, Sasaki T, del Barco Barrantes I, et al. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol. 1998;8:1169\u201378.","journal-title":"Curr Biol"},{"key":"1497_CR19","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1038\/onc.2015.462","volume":"35","author":"M Tesio","year":"2016","unstructured":"Tesio M, Trinquand A, Macintyre E, Asnafi V. Oncogenic PTEN functions and models in T-cell malignancies. Oncogene. 2016;35:3887\u201396.","journal-title":"Oncogene"},{"key":"1497_CR20","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1126\/science.285.5436.2122","volume":"285","author":"A Di Cristofano","year":"1999","unstructured":"Di Cristofano A, Kotsi P, Peng YF, Cordon-Cardo C, Elkon KB, Pandolfi PP. Impaired Fas response and autoimmunity in Pten+\/- mice. Science. 1999;285:2122\u20135.","journal-title":"Science"},{"key":"1497_CR21","doi-asserted-by":"publisher","first-page":"4591","DOI":"10.1096\/fj.201902751R","volume":"34","author":"Q Zhu","year":"2020","unstructured":"Zhu Q, Dong H, Bukhari AA, Zhao A, Li M, Sun Y, et al. HUWE1 promotes EGFR ubiquitination and degradation to protect against renal tubulointerstitial fibrosis. FASEB J. 2020;34:4591\u2013601.","journal-title":"FASEB J"},{"key":"1497_CR22","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/s41589-021-00831-5","volume":"17","author":"DB Grabarczyk","year":"2021","unstructured":"Grabarczyk DB, Petrova OA, Deszcz L, Kurzbauer R, Murphy P, Ahel J, et al. HUWE1 employs a giant substrate-binding ring to feed and regulate its HECT E3 domain. Nat Chem Biol. 2021;17:1084\u201392.","journal-title":"Nat Chem Biol"},{"key":"1497_CR23","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1093\/nar\/gkv325","volume":"43","author":"J Yi","year":"2015","unstructured":"Yi J, Lu G, Li L, Wang X, Cao L, Lin M, et al. DNA damage-induced activation of CUL4B targets HUWE1 for proteasomal degradation. Nucleic Acids Res. 2015;43:4579\u201390.","journal-title":"Nucleic Acids Res"},{"key":"1497_CR24","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1073\/pnas.0308217100","volume":"101","author":"SA Backman","year":"2004","unstructured":"Backman SA, Ghazarian D, So K, Sanchez O, Wagner KU, Hennighausen L, et al. Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten. Proc Natl Acad Sci USA. 2004;101:1725\u201330.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1497_CR25","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.isci.2019.10.047","volume":"21","author":"H Doan","year":"2019","unstructured":"Doan H, Parsons A, Devkumar S, Selvarajah J, Miralles F, Carroll VA. HIF-mediated Suppression of DEPTOR Confers Resistance to mTOR Kinase Inhibition in Renal Cancer. iScience. 2019;21:509\u201320.","journal-title":"iScience"},{"key":"1497_CR26","doi-asserted-by":"publisher","first-page":"4589","DOI":"10.7314\/APJCP.2014.15.11.4589","volume":"15","author":"EY Lai","year":"2014","unstructured":"Lai EY, Chen ZG, Zhou X, Fan XR, Wang H, Lai PL, et al. DEPTOR expression negatively correlates with mTORC1 activity and tumor progression in colorectal cancer. Asian Pac J Cancer Prev. 2014;15:4589\u201394.","journal-title":"Asian Pac J Cancer Prev"},{"key":"1497_CR27","doi-asserted-by":"publisher","first-page":"14188","DOI":"10.18632\/oncotarget.7420","volume":"7","author":"YM Ji","year":"2016","unstructured":"Ji YM, Zhou XF, Zhang J, Zheng X, Li SB, Wei ZQ, et al. DEPTOR suppresses the progression of esophageal squamous cell carcinoma and predicts poor prognosis. Oncotarget. 2016;7:14188\u201398.","journal-title":"Oncotarget"},{"key":"1497_CR28","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1158\/1541-7786.MCR-15-0480","volume":"14","author":"X Zhou","year":"2016","unstructured":"Zhou X, Guo J, Ji Y, Pan G, Liu T, Zhu H, et al. Reciprocal Negative Regulation between EGFR and DEPTOR Plays an Important Role in the Progression of Lung Adenocarcinoma. Mol Cancer Res. 2016;14:448\u201357.","journal-title":"Mol Cancer Res"},{"key":"1497_CR29","doi-asserted-by":"publisher","first-page":"12811","DOI":"10.18632\/oncotarget.2659","volume":"5","author":"H Li","year":"2014","unstructured":"Li H, Sun GY, Zhao Y, Thomas D, Greenson JK, Zalupski MM, et al. DEPTOR has growth suppression activity against pancreatic cancer cells. Oncotarget. 2014;5:12811\u20139.","journal-title":"Oncotarget"},{"key":"1497_CR30","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13046-016-0484-y","volume":"36","author":"V Catena","year":"2017","unstructured":"Catena V, Fanciulli M. Deptor: not only a mTOR inhibitor. J Exp Clin Cancer Res. 2017;36:12.","journal-title":"J Exp Clin Cancer Res"},{"key":"1497_CR31","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1593\/neo.12542","volume":"14","author":"Z Wang","year":"2012","unstructured":"Wang Z, Zhong J, Inuzuka H, Gao D, Shaik S, Sarkar FH, et al. An evolving role for DEPTOR in tumor development and progression. Neoplasia. 2012;14:368\u201375.","journal-title":"Neoplasia"},{"key":"1497_CR32","doi-asserted-by":"publisher","first-page":"6355","DOI":"10.7150\/thno.51286","volume":"11","author":"Y Bi","year":"2021","unstructured":"Bi Y, Chen X, Wei B, Wang L, Gong L, Li H, et al. DEPTOR stabilizes ErbB2 to promote the proliferation and survival of ErbB2-positive breast cancer cells. Theranostics. 2021;11:6355\u201369.","journal-title":"Theranostics"},{"key":"1497_CR33","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1007\/s00277-013-1770-9","volume":"92","author":"ZZ Xu","year":"2013","unstructured":"Xu ZZ, Xia ZG, Wang AH, Wang WF, Liu ZY, Chen LY, et al. Activation of the PI3K\/AKT\/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab. Ann Hematol. 2013;92:1351\u20138.","journal-title":"Ann Hematol"},{"key":"1497_CR34","doi-asserted-by":"publisher","first-page":"14304","DOI":"10.3390\/molecules190914304","volume":"19","author":"A Majchrzak","year":"2014","unstructured":"Majchrzak A, Witkowska M, Smolewski P. Inhibition of the PI3K\/Akt\/mTOR signaling pathway in diffuse large B-cell lymphoma: current knowledge and clinical significance. Molecules. 2014;19:14304\u201315.","journal-title":"Molecules"},{"key":"1497_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2021.109770","volume":"351","author":"C Ma","year":"2022","unstructured":"Ma C, Liu M, Zhang J, Cai H, Wu Y, Zhang Y, et al. ZCL-082, a boron-containing compound, induces apoptosis of non-Hodgkin\u2019s lymphoma via targeting p90 ribosomal S6 kinase 1\/NF-kappaB signaling pathway. Chem Biol Interact. 2022;351:109770.","journal-title":"Chem Biol Interact"},{"key":"1497_CR36","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.3390\/ijms22073716","volume":"22","author":"Z Spinello","year":"2021","unstructured":"Spinello Z, Fregnani A, Quotti Tubi L, Trentin L, Piazza F, Manni S. Targeting Protein Kinases in Blood Cancer: Focusing on CK1alpha and CK2. Int J Mol Sci. 2021;22:3716.","journal-title":"Int J Mol Sci"},{"key":"1497_CR37","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1080\/15384047.2019.1683332","volume":"21","author":"N Cai","year":"2020","unstructured":"Cai N, Chen Z, Huang Y, Shao S, Yu H, Wang Y, et al. beta-TrCP1 promotes cell proliferation via TNF-dependent NF-kappaB activation in diffuse large B cell lymphoma. Cancer Biol Ther. 2020;21:241\u201347.","journal-title":"Cancer Biol Ther"},{"key":"1497_CR38","doi-asserted-by":"publisher","first-page":"6204","DOI":"10.3390\/ijms13056204","volume":"13","author":"CF Qi","year":"2012","unstructured":"Qi CF, Kim YS, Xiang S, Abdullaev Z, Torrey TA, Janz S, et al. Characterization of ARF-BP1\/HUWE1 interactions with CTCF, MYC, ARF and p53 in MYC-driven B cell neoplasms. Int J Mol Sci. 2012;13:6204\u201319.","journal-title":"Int J Mol Sci"},{"key":"1497_CR39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/1878-0261.12155","volume":"12","author":"S Sigismund","year":"2018","unstructured":"Sigismund S, Avanzato D, Lanzetti L. Emerging functions of the EGFR in cancer. Mol Oncol. 2018;12:3\u201320.","journal-title":"Mol Oncol"},{"key":"1497_CR40","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1126\/science.1099314","volume":"304","author":"JG Paez","year":"2004","unstructured":"Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497\u2013500.","journal-title":"Science"},{"key":"1497_CR41","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMe0806778","volume":"359","author":"WA Messersmith","year":"2008","unstructured":"Messersmith WA, Ahnen DJ. Targeting EGFR in colorectal cancer. N Engl J Med. 2008;359:1834\u20136.","journal-title":"N Engl J Med"},{"key":"1497_CR42","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3390\/ijms22020587","volume":"22","author":"A Oprita","year":"2021","unstructured":"Oprita A, Baloi SC, Staicu GA, Alexandru O, Tache DE, Danoiu S, et al. Updated Insights on EGFR Signaling Pathways in Glioma. Int J Mol Sci. 2021;22:587.","journal-title":"Int J Mol Sci"},{"key":"1497_CR43","doi-asserted-by":"publisher","first-page":"770","DOI":"10.3390\/jpm13050770","volume":"13","author":"S Qazi","year":"2023","unstructured":"Qazi S, Uckun FM. Upregulated Expression of ErbB1 in Diffuse Large B-Cell Lymphoma as a Predictor of Poor Overall Survival Outcome. J Pers Med. 2023;13:770.","journal-title":"J Pers Med"},{"key":"1497_CR44","first-page":"2209","volume":"21","author":"J Jin","year":"2020","unstructured":"Jin J, Wang L, Tao Z, Zhang J, Lv F, Cao J, et al. PDGFD induces ibrutinib resistance of diffuse large B\u2011cell lymphoma through activation of EGFR. Mol Med Rep. 2020;21:2209\u201319.","journal-title":"Mol Med Rep"},{"key":"1497_CR45","first-page":"1209","volume":"13","author":"L Nie","year":"2023","unstructured":"Nie L, Wang YN, Hsu JM, Hou J, Chu YY, Chan LC, et al. Nuclear export signal mutation of epidermal growth factor receptor enhances malignant phenotypes of cancer cells. Am J Cancer Res. 2023;13:1209\u201339.","journal-title":"Am J Cancer Res"},{"key":"1497_CR46","doi-asserted-by":"crossref","unstructured":"Nie L, Hou J, Chu Y-Y, Wnag Y-N, Chan L-C, Huo L, et al. Compartmentalized functions of epidermal growth factor receptor (EGFR) in tumorigenesis and malignant phenotypes. Cancer Res. 2021;81:Abstract nr 120.","DOI":"10.1158\/1538-7445.AM2021-120"},{"key":"1497_CR47","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S1097-2765(00)80308-1","volume":"3","author":"R Sears","year":"1999","unstructured":"Sears R, Leone G, DeGregori J, Nevins JR. Ras enhances Myc protein stability. Mol Cell. 1999;3:169\u201379.","journal-title":"Mol Cell"},{"key":"1497_CR48","doi-asserted-by":"publisher","first-page":"3663","DOI":"10.1101\/gad.12.23.3663","volume":"12","author":"G Levkowitz","year":"1998","unstructured":"Levkowitz G, Waterman H, Zamir E, Kam Z, Oved S, Langdon WY, et al. c-Cbl\/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev. 1998;12:3663\u201374.","journal-title":"Genes Dev"},{"key":"1497_CR49","doi-asserted-by":"publisher","first-page":"22151","DOI":"10.1074\/jbc.274.32.22151","volume":"274","author":"H Waterman","year":"1999","unstructured":"Waterman H, Levkowitz G, Alroy I, Yarden Y. The RING finger of c-Cbl mediates desensitization of the epidermal growth factor receptor. J Biol Chem. 1999;274:22151\u20134.","journal-title":"J Biol Chem"},{"key":"1497_CR50","doi-asserted-by":"publisher","first-page":"7038","DOI":"10.1074\/jbc.M408575200","volume":"280","author":"E Kario","year":"2005","unstructured":"Kario E, Marmor MD, Adamsky K, Citri A, Amit I, Amariglio N, et al. Suppressors of cytokine signaling 4 and 5 regulate epidermal growth factor receptor signaling. J Biol Chem. 2005;280:7038\u201348.","journal-title":"J Biol Chem"},{"key":"1497_CR51","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.str.2007.09.016","volume":"15","author":"AN Bullock","year":"2007","unstructured":"Bullock AN, Rodriguez MC, Debreczeni JE, Songyang Z, Knapp S. Structure of the SOCS4-ElonginB\/C complex reveals a distinct SOCS box interface and the molecular basis for SOCS-dependent EGFR degradation. Structure. 2007;15:1493\u2013504.","journal-title":"Structure"},{"key":"1497_CR52","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.semcancer.2020.04.003","volume":"67","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Xiong X, Sun Y. Cullin-RING Ligase 5: Functional characterization and its role in human cancers. Semin Cancer Biol. 2020;67:61\u201379.","journal-title":"Semin Cancer Biol"},{"key":"1497_CR53","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00018-022-04320-3","volume":"79","author":"T Zhou","year":"2022","unstructured":"Zhou T, Chen T, Lai B, Zhang W, Luo X, Xia D, et al. FBXW2 inhibits prostate cancer proliferation and metastasis via promoting EGFR ubiquitylation and degradation. Cell Mol Life Sci. 2022;79:268.","journal-title":"Cell Mol Life Sci"},{"key":"1497_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26222-x","volume":"12","author":"M Niu","year":"2021","unstructured":"Niu M, Xu J, Liu Y, Li Y, He T, Ding L, et al. FBXL2 counteracts Grp94 to destabilize EGFR and inhibit EGFR-driven NSCLC growth. Nat Commun. 2021;12:5919.","journal-title":"Nat Commun"},{"key":"1497_CR55","doi-asserted-by":"publisher","first-page":"12661","DOI":"10.1074\/jbc.RA120.013519","volume":"295","author":"P Ray","year":"2020","unstructured":"Ray P, Raghunathan K, Ahsan A, Allam US, Shukla S, Basrur V, et al. Ubiquitin ligase SMURF2 enhances epidermal growth factor receptor stability and tyrosine-kinase inhibitor resistance. J Biol Chem. 2020;295:12661\u201373.","journal-title":"J Biol Chem"},{"key":"1497_CR56","doi-asserted-by":"publisher","first-page":"16307","DOI":"10.1074\/jbc.RA118.002887","volume":"293","author":"SR Ho","year":"2018","unstructured":"Ho SR, Lin WC. RNF144A sustains EGFR signaling to promote EGF-dependent cell proliferation. J Biol Chem. 2018;293:16307\u201323.","journal-title":"J Biol Chem"},{"key":"1497_CR57","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12929-018-0470-0","volume":"25","author":"SH Kao","year":"2018","unstructured":"Kao SH, Wu HT, Wu KJ. Ubiquitination by HUWE1 in tumorigenesis and beyond. J Biomed Sci. 2018;25:67.","journal-title":"J Biomed Sci"},{"key":"1497_CR58","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.cmet.2014.01.001","volume":"19","author":"J Li","year":"2014","unstructured":"Li J, Kim SG, Blenis J. Rapamycin: one drug, many effects. Cell Metab. 2014;19:373\u20139.","journal-title":"Cell Metab"},{"key":"1497_CR59","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.celrep.2019.12.032","volume":"30","author":"D Cui","year":"2020","unstructured":"Cui D, Xiong X, Shu J, Dai X, Sun Y, Zhao Y. FBXW7 Confers Radiation Survival by Targeting p53 for Degradation. Cell Rep. 2020;30:497\u2013509.e4.","journal-title":"Cell Rep"},{"key":"1497_CR60","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/1878-0261.12403","volume":"13","author":"Y Ma","year":"2019","unstructured":"Ma Y, Cui D, Xiong X, Inuzuka H, Wei W, Sun Y, et al. SCFbeta-TrCP ubiquitinates CHK1 in an AMPK-dependent manner in response to glucose deprivation. Mol Oncol. 2019;13:307\u201321.","journal-title":"Mol Oncol"}],"container-title":["Cell Death &amp; Differentiation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41418-025-01497-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-025-01497-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-025-01497-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T15:05:29Z","timestamp":1759763129000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41418-025-01497-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":60,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1497"],"URL":"https:\/\/doi.org\/10.1038\/s41418-025-01497-5","relation":{},"ISSN":["1350-9047","1476-5403"],"issn-type":[{"value":"1350-9047","type":"print"},{"value":"1476-5403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]},"assertion":[{"value":"8 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal experiments were ethically approved by the Animal Care and Use Committee of Zhejiang University and the University of Michigan Committee on Use and Care of Animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}